Unlike other steroid hormone receptors driving the proliferation of hormone-dependent cancers, glucocorticoid receptor (GR) activation leads to growth arrest and apoptosis induction in lymphoid tissue that underlies the use of GR agonists for lymphoid cancer treatment and makes them one of the key components of multimodal treatment protocols of T-ALL [591]. Here, NR3C1 is linked to lymphoma.